Company intelligence
ABD Search
Connecting Industry Specialists who Accelerate Rare Disease & Orphan Drug Development.
About ABD Search
ABD Search is a founder-led life science recruitment partner specialising in rare disease and orphan drug programmes, with a single senior consultant managing every search from brief to offer. We work with lean, mission-driven organisations across the entire development lifecycle — from discovery and early clinical stage through regulatory approval, launch and commercialisation. That spans the full range of roles a rare disease programme depends on: research, quality, CMC and clinical through to regulatory affairs, market access, medical affairs and commercial — alongside the executive and leadership hires that set a programme's direction. We're also deeply networked with the key opinion leaders shaping the field. The leaner model is intentional. Lower overheads make a transparent partnership fee possible, and long-term collaboration replaces volume-led placement work. For rare disease programmes where capital is precious and every hire matters, a level of partnership and pricing once reserved for large-scale managed recruitment arrangements is now workable for organisations at any stage.
Verified activity
Signals from ABD Search
2 published signals
Capital & Finance
ABD Search announced that the ERDERA Clinical Trial Call 2026 closes its expression of interest stage on 10 September with up to €30 million available for multinational Phase I, Phase I/II, and Phase II trials in rare diseases.
Reported by ABD Search
Legal & Regulatory
ABD Search notes that Palvella Therapeutics completed its rolling NDA submission to the FDA for QTORIN rapamycin in microcystic lymphatic malformations, with the submission completed yesterday.
Reported by ABD Search